Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +56.7 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599204 |
| 2 | = | Malignant Bladder Neoplasm | +23.3 | 96.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599205 |
| 3 | = | Cutaneous Melanoma | +20 | 93.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599206 |
| 4 | = | Malignant Laryngeal Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599207 |
| 5 | = | Malignant Pancreatic Neoplasm | +10 | 86.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599208 |
| 5 | = | Malignant Vaginal Neoplasm | +10 | 86.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599209 |
| 5 | = | Malignant Vulvar Neoplasm | +10 | 86.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599210 |
| 8 | = | Malignant Esophageal Neoplasm | +3.4 | 76.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599211 |
| 9 | = | Malignant Kidney Neoplasm | +3.3 | 73.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599213 |
| 9 | = | Malignant Mesothelioma | +3.3 | 73.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599212 |
| 11 | = | Malignant Lung Neoplasm | 0 | 66.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599214 |
| 11 | = | Malignant Prostate Neoplasm | 0 | 66.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599216 |
| 11 | = | Malignant Rectal Neoplasm | 0 | 66.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599218 |
| 11 | = | Malignant Salivary Gland Neoplasm | 0 | 66.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599215 |
| 11 | = | Malignant Testicular Neoplasm | 0 | 66.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599217 |
| 16 | = | Malignant Liver Neoplasm | -3.3 | 50 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599219 |
| 16 | = | Malignant Thyroid Gland Neoplasm | -3.3 | 50 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599220 |
| 18 | = | Malignant Anal Neoplasm | -3.3 | 43.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599221 |
| 19 | = | Malignant Breast Neoplasm | -3.4 | 40 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599222 |
| 19 | = | Malignant Central Nervous System Neoplasm | -3.4 | 40 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599223 |
| 21 | = | Malignant Hypopharyngeal Neoplasm | -6.7 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599224 |
| 21 | = | Malignant Penile Neoplasm | -6.7 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599225 |
| 23 | = | Leukemia | -6.7 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599226 |
| 23 | = | Malignant Ovarian Neoplasm | -6.7 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599227 |
| 25 | = | Hodgkin Lymphoma | -10 | 20 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599228 |
| 26 | = | Malignant Uterine Corpus Neoplasm | -13.3 | 16.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599229 |
| 27 | = | Malignant Gastric Neoplasm | -13.4 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599230 |
| 28 | = | Multiple Myeloma | -16.6 | 10 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599231 |
| 28 | = | Non-Hodgkin Lymphoma | -16.6 | 10 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599232 |
| 30 | = | Malignant Cervical Neoplasm | -16.7 | 3.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599233 |
| 31 | = | Malignant Nasopharyngeal Neoplasm | -30 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2599234 |
Data updated 16 hours agoSource updated unknown31 eligible entities · inputs hash 937557e186e3830e694b002d